Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases

J Clin Endocrinol Metab. 2000 Jul;85(7):2355-63. doi: 10.1210/jcem.85.7.6702.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bone Diseases, Metabolic / drug therapy*
  • Bone Diseases, Metabolic / physiopathology*
  • Glycoproteins / physiology*
  • Glycoproteins / therapeutic use*
  • Humans
  • Ligands
  • NF-kappa B / genetics
  • NF-kappa B / physiology*
  • Osteoprotegerin
  • Receptors, Cytoplasmic and Nuclear*
  • Receptors, Tumor Necrosis Factor
  • Recombinant Proteins

Substances

  • Glycoproteins
  • Ligands
  • NF-kappa B
  • Osteoprotegerin
  • Receptors, Cytoplasmic and Nuclear
  • Receptors, Tumor Necrosis Factor
  • Recombinant Proteins
  • TNFRSF11B protein, human